Oral hydroxychloroquine showed no clear difference in primary outcome: partial clinical response compared with placebo (low certainty).
Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher partcipant assessment of success compared with placebo (moderate certainty).
Summary of Findings Table ‐ IncobotulinumtoxinA 20U probably leads to higher participant assessment of success by analysing scores and scales ‐ 4… compared with placebo (moderate certainty).
Summary of Findings Table ‐ IncobotulinumtoxinA 20U probably leads to higher physician assessment of success by analysing scores and scales compared with placebo (moderate certainty).
Summary of Findings Table ‐ IncobotulinumtoxinA 20U showed no clear difference in total adverse events compared with placebo (low certainty).
The review found no eligible studies for this question.
Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher major adverse events compared with placebo (moderate certainty).
Summary of Findings Table ‐ DaxibotulinumtoxinA 40U probably leads to higher participant assessment of success by analysing scores and scales ‐ 4… compared with placebo (moderate certainty).
Summary of Findings Table ‐ DaxibotulinumtoxinA 40U probably leads to higher physician assessment of success by analysing scores and scales ‐ 4… compared with placebo (moderate certainty).
Summary of Findings Table ‐ DaxibotulinumtoxinA 40U probably leads to higher total adverse events compared with placebo (moderate certainty).
Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher physician assessment of success compared with placebo (moderate certainty).
Summary of Findings Table ‐ OnabotulinumtoxinA 20U showed no clear difference in total adverse events compared with placebo (low certainty).
Summary of Findings Table ‐ AbobotulinumtoxinA 50U leads to higher participant assessment of success by analysing scores and scales ‐… compared with placebo (high certainty).
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in major adverse events (eyelid ptosis, eyelid sensory disorder,… compared with placebo (moderate certainty).